Bristol Myers Squibb Reports Positive Phase 2 QUINTESSENTIAL Results for Arlo-Cel in Heavily Pretreated Multiple Myeloma
Bristol Myers Squibb (NYSE: BMY) announced positive Phase 2 results from the registrational QUINTESSENTIAL trial evaluating arlocabtagene autoleucel (arlo-cel; BMS-986393) in adults with quadruple-class exposed relapsed and refractory multiple myeloma (RRMM). The findings support the potential of arlo-cel as a new treatment approach for patients whose disease has been exposed to multiple major classes of multiple myeloma therapies, including prior BCMA-targeted treatment.
The QUINTESSENTIAL study met its primary endpoint, demonstrating a statistically significant and clinically meaningful overall response rate (ORR) among patients with quadruple-class exposed RRMM who had received four or more prior lines of therapy. The study also achieved multiple key secondary endpoints, including complete response rate (CRR) in the same patient population, as well as ORR and CRR among patients who had received three or more prior lines of therapy.
Arlo-cel is being developed as a potential first-in-class autologous G protein-coupled receptor class C group 5 member D (GPRC5D)-directed chimeric antigen receptor (CAR) T-cell therapy. Designed as a single-infusion treatment, arlo-cel could offer a differentiated cell therapy approach for patients with heavily pretreated RRMM, particularly those whose disease has become resistant to therapies targeting other established multiple myeloma proteins.
The safety profile observed in QUINTESSENTIAL was consistent with the known safety profiles of other CAR T-cell therapies and GPRC5D-targeting therapies used in multiple myeloma.
QUINTESSENTIAL Meets Primary Endpoint
The registrational QUINTESSENTIAL trial (NCT06297226) evaluated arlo-cel in adults with relapsed and refractory multiple myeloma who had received multiple previous treatment regimens.
The primary endpoint was overall response rate in patients with quadruple-class exposed disease following four or more prior lines of therapy. The study achieved this endpoint, with arlo-cel producing a statistically significant and clinically meaningful ORR in the evaluated population.
The results are particularly relevant because the patient population enrolled in the study represents a group with substantial unmet medical needs. Patients who have progressed after multiple treatment classes generally have fewer therapeutic options available, while disease control can become increasingly difficult as the disease develops resistance to previously used medicines.
The QUINTESSENTIAL results suggest that targeting GPRC5D with CAR T-cell therapy may provide another avenue for treatment after patients have already received therapies directed against several other important multiple myeloma targets.
Bristol Myers Squibb said the results support the potential benefit of arlo-cel in this heavily pretreated population.
Multiple Secondary Endpoints Also Achieved
In addition to meeting the primary endpoint, the QUINTESSENTIAL trial achieved the key secondary endpoint of complete response rate in patients with quadruple-class exposed RRMM who had received four or more prior lines of therapy.
The study also met key secondary endpoints evaluating ORR and CRR in patients with RRMM who had received three or more prior lines of therapy.
The achievement of these endpoints provides additional evidence of arlo-cel’s activity across different levels of prior treatment exposure.
Overall response rate measures the proportion of patients whose disease demonstrates a defined response to treatment, while complete response represents a deeper level of disease control. In multiple myeloma, achieving deeper responses can be an important component of treatment evaluation, particularly among patients with heavily pretreated and treatment-resistant disease.
Bristol Myers Squibb has not released the complete numerical results from QUINTESSENTIAL in its announcement. The company said the detailed findings will be presented at an upcoming medical meeting.
Quadruple-Class Exposed Patients Represent a Growing Challenge
The QUINTESSENTIAL population reflects an increasingly important challenge in multiple myeloma treatment.
Quadruple-class exposed patients are those who have previously received an immunomodulatory drug (IMiD), a proteasome inhibitor (PI), an anti-CD38 therapy and a BCMA-targeted therapy.
As combination treatment regimens are increasingly used earlier in the multiple myeloma treatment journey, patients can become exposed to several different therapeutic classes relatively quickly.
When disease progresses after exposure to all four of these major treatment categories, clinicians face a particularly difficult treatment landscape. The disease may be resistant to multiple established mechanisms, creating an urgent need for therapies that work through alternative biological targets.
Lynelle B. Hoch, president of the Cell Therapy Organization at Bristol Myers Squibb, emphasized the growing importance of this patient population.
“As combination treatment regimens are now frequently used in earlier lines of therapy, an increasing number of people with multiple myeloma are quadruple-class exposed and resistant to currently available therapies earlier in the treatment journey, creating a critical need for new therapeutic approaches,” Hoch said.
The company believes arlo-cel could address part of this treatment gap by targeting GPRC5D rather than relying on BCMA as its primary target.
GPRC5D Provides an Alternative Target
A central feature of arlo-cel’s development program is its targeting of GPRC5D.
GPRC5D is a protein that has emerged as a potential therapeutic target in multiple myeloma. The development of GPRC5D-directed therapies reflects the broader effort to identify alternative targets for patients whose disease has progressed following BCMA-directed treatment.
This is particularly important because BCMA-targeted therapies have become an increasingly important part of multiple myeloma treatment. As more patients receive BCMA-directed therapies earlier in their disease journey, there is a growing need for effective treatments that can be used after BCMA exposure.
Arlo-cel is designed to direct a patient’s own genetically modified T cells toward GPRC5D-expressing myeloma cells. As an autologous CAR T-cell therapy, the treatment uses cells collected from the individual patient and modified to recognize the selected cancer target.
Bristol Myers Squibb said the approach could help provide a differentiated treatment option for patients who have already been treated with BCMA-targeted therapies.
Potential Role After BCMA-Targeted Therapy
The inclusion of patients previously treated with BCMA-targeted therapies is an important aspect of the QUINTESSENTIAL development program.
BCMA has become a major target in multiple myeloma, with several therapeutic approaches developed around the protein. However, patients whose disease progresses after BCMA-directed treatment may have limited options, particularly when they have also received other major treatment classes.
Arlo-cel’s GPRC5D-directed mechanism is intended to provide an alternative approach for these patients.
Hoch said the QUINTESSENTIAL topline findings support the potential benefit of arlo-cel and highlighted the importance of targeting alternative proteins such as GPRC5D using cell therapy.
She said the findings could lay the foundation for arlo-cel to become an important treatment option for patients who have been exposed to prior BCMA-targeted therapies.
Single-Infusion Cell Therapy Approach
Another potentially differentiating feature of arlo-cel is its design as a single-infusion CAR T-cell treatment.
CAR T-cell therapies are developed by collecting a patient’s immune cells, genetically modifying them to recognize a specific cancer-associated target and returning the modified cells to the patient.
The single-infusion approach means that, once the product is prepared for administration, treatment is delivered as a single therapeutic infusion rather than requiring repeated dosing over an extended period.
For patients with heavily pretreated multiple myeloma, treatment convenience and the ability to achieve meaningful disease control with a single cellular therapy intervention may be important considerations.
However, CAR T-cell treatment involves a specialized manufacturing and treatment process, and patients require careful clinical management. The complete QUINTESSENTIAL dataset will provide additional information about the treatment’s efficacy and safety profile.
Safety Profile Consistent With Expectations
Bristol Myers Squibb reported that the safety profile of arlo-cel was consistent with that observed with other CAR T-cell therapies and other GPRC5D-targeting therapies in multiple myeloma.
The company did not identify an unexpected safety profile in the topline announcement.
Safety remains an important consideration in the development of CAR T-cell therapies because these treatments involve powerful immune-cell activation and require specialized monitoring and management.
The company’s statement that the safety profile was consistent with expectations provides an initial assessment of arlo-cel’s tolerability in the QUINTESSENTIAL population. More detailed safety findings are expected when the full study data are presented at a future medical meeting.
Expanding Treatment Options in Multiple Myeloma
Multiple myeloma treatment has evolved considerably, with patients now able to receive therapies directed against several different biological targets and mechanisms. However, the increasing use of these treatments has also created a new challenge: patients may progress after receiving multiple classes of therapy and become resistant to several available options.
Quadruple-class exposed RRMM represents one of the clearest examples of this unmet need.
For these patients, therapies that use a different target or mechanism may be particularly valuable. The QUINTESSENTIAL results provide support for continued development of GPRC5D-directed CAR T-cell therapy as one potential strategy.
The findings also highlight the potential value of cell therapy beyond the BCMA target. As the multiple myeloma treatment landscape continues to evolve, alternative targets could become increasingly important for sequencing therapies and addressing treatment resistance.
Detailed Results Expected at Upcoming Medical Meeting
Bristol Myers Squibb plans to present detailed results from the QUINTESSENTIAL trial at an upcoming medical meeting.
The complete presentation is expected to provide additional information about the magnitude and durability of responses, complete response rates, patient characteristics, safety outcomes and other clinically relevant measures.
Further data will also help clarify the potential role of arlo-cel across patients with different levels of prior treatment exposure, including those treated with three or more previous lines and those with quadruple-class exposed disease after four or more prior lines.
The company thanked patients and investigators participating in the QUINTESSENTIAL clinical trial, acknowledging their contribution to the development of a potential new therapy for a population with significant unmet medical needs.
Potential New Option for Heavily Pretreated RRMM
The positive Phase 2 QUINTESSENTIAL results mark an important milestone in Bristol Myers Squibb’s development of arlocabtagene autoleucel.
By meeting its primary endpoint and multiple key secondary endpoints, the study provides clinical evidence supporting arlo-cel’s potential in heavily pretreated relapsed and refractory multiple myeloma.
The results are particularly significant for patients who have been exposed to four major treatment classes, including BCMA-targeted therapy. As more patients receive combination regimens earlier in their treatment journey, this population is expected to become increasingly relevant to clinical practice.
Arlo-cel’s GPRC5D-directed mechanism offers a different target from BCMA-directed therapies, while its single-infusion CAR T-cell design represents another potential approach to treating advanced multiple myeloma.
With the full QUINTESSENTIAL findings scheduled for presentation at an upcoming medical meeting, Bristol Myers Squibb will continue evaluating arlo-cel’s potential to address the needs of patients with heavily pretreated disease. If supported by the complete clinical dataset and future regulatory review, the therapy could eventually add another treatment option for people with RRMM whose disease has progressed after multiple established therapeutic approaches.
About QUINTESSENTIAL
QUINTESSENTIAL (NCT06297226) is a Phase 2, open-label, multicenter, single-arm study evaluating the efficacy and safety of arlocabtagene autoleucel (arlo-cel; BMS986393) in patients with quadruple-class exposed relapsed and refractory multiple myeloma (RRMM). Quadruple-class exposed consists of those who have been treated with an immunomodulatory inhibitor (IMiD), a proteasome inhibitor (PI), an anti-CD38 therapy and a BCMA-targeted therapy. The trial included patients who had received prior treatment with CAR T cell therapies.
The primary endpoint of the study is overall response rate (ORR), defined as best overall response (BOR) of partial response (PR) or better in quadruple-class exposed patients who had received four or more prior lines of therapy. Key secondary endpoints include complete response rate (CRR) in patients with RRMM who had been quadruple-class exposed after four or more prior lines of therapy, and ORR and CRR in quadruple-class exposed patients who had received three or more prior lines of therapy.
About Arlocabtagene Autoleucel
Arlocabtagene autoleucel (arlo-cel; BMS-986393) is a potential first-in-class autologous G protein-coupled receptor class C group 5 member D (GPRC5D)-directed chimeric antigen receptor (CAR) T cell therapy. GPRC5D is a receptor expressed on plasma cells in multiple myeloma, with limited expression on healthy cells, and is a validated therapeutic target in multiple myeloma. Its expression is independent of BCMA expression and is maintained even after prior BCMA-directed therapy. Arlo-cel is designed to recognize and bind to GPRC5D in order to target and eliminate GPRC5D-expressing myeloma cells.